3 Stocks With the Most Upside by the End of 2026
Analysts remain optimistic that the market will view upcoming catalysts in a bullish light.
Overview
Are you hoping for a better performance from your portfolio in the latter half of this year than you achieved during the first half? It may require a slightly different selection of stocks.
Here's a closer look at three of the market's better-known names with more near-term upside than most other tickers. Namely, each of these stocks is currently priced well below analysts' consensus, although there's far more working in their favor than just this relative discount.
Details
Shares of gene-editing drug specialist CRISPR Therapeutics (NASDAQ: CRSP) have been stuck in neutral since 2022. Although its first-ever approved drug Casgevy works well enough as a therapy for sickle cell disease, since each patient's treatment is custom-built, it can take several months -- even up to a year -- to complete the process.
Source
Originally published at www.fool.com.